TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01556022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRCs processed by the Celution System
Description: Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Lactated Ringer's and Subject's Blood
Description: Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
Study: NCT01829620

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: This is standard outpatient mental health care that is routinely provided in study site outpatient clinics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCVT+TAU
Description: Participants in the CCVT + TAU condition will receive caring texts at 1 day, 1 week, 1, 2, 3, 4, 6, 8, 10, \& 12 months, and on their birthday. Text messages will indicate a general concern for the individual and a link to a website with general resources including behavioral health and crisis services.~Participants in both conditions will continue to receive usual behavioral health care according to standard operating procedures.
Study: NCT04106557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gaboxadol
Description: OV101 versus placebo once daily at bedtime for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules to OV101 capsules.
Study: NCT02388308

Intervention type: DEVICE
Intervention: Clarity ultrasound
Description: Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.

Intervention type: DEVICE
Intervention: Clarity ultrasound
Description: Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.

Intervention type: DEVICE
Intervention: Clarity ultrasound
Description: Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.

Intervention type: DEVICE
Intervention: Clarity ultrasound
Description: Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.
Study: NCT03512821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol 500 MG
Description: Ursodiol 500mg tablets followed by Urso Forte 500mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urso Forte 500Mg Tablet
Description: Urso forte 500mg tablets followed by Ursodiol 500mg tablets
Study: NCT01893307

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMPT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Beam Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo IMPT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02323789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.
Study: NCT04847193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention 2: Xanthohumol and Iso-alpha acids
Description: Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
Study: NCT00901836

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative proton therapy
Description: 28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Standard of care surgery will be performed 4-6 weeks after completion of radiation.
Study: NCT03391401

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Any bariatric operation that is considered as a standard procedure in bariatric surgery (i.e. sleeve gastrectomy, roux-en-y gastric bypass, mini-gastric / one anastomosis gastric bypass, redo and revisional bariatric surgery).
Study: NCT00883051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
Study: NCT05657340

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Video-head impulse testing
Description: Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video-head impulse testing
Description: Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.
Study: NCT00883051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02963246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness-based therapy has been used effectively to treat a variety of physical and psychological disorders, including depression, anxiety, and chronic pain. Recently, several lines of research have explored the potential for mindfulness-therapy in treating somatization disorders, including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome. Mindfulness-based therapies (MBT) are a clinical application involving the key element of nonjudgmental acceptance of physical pain or psychological distress, thereby reducing the tendency to ruminate over and catastrophise these experiences.~In the present study, we propose a mindfulness intervention of 12 months, with sessions either personalized or online.
Study: NCT02783768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham
Description: The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham
Description: The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 3-Helium
Description: Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 3-Helium
Description: Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).
Study: NCT02451722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyboot shoes
Description: The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyboot shoes
Description: The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure
Study: NCT03365102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS over the rIFG,
Description: tDCS at a constant current of 1.5 milliampere (mA) will be applied for one 20-minute session over the right inferior frontal gyrus . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
Study: NCT03397732

Intervention type: PROCEDURE
Intervention: aorto-bifemoral bypass and aorta stentgraft
Description: Surgical implantation of aorto-bifemoral bypass or aorta stentgraft under general and/or regional anaesthesia.

Intervention type: PROCEDURE
Intervention: aorto-bifemoral bypass and aorta stentgraft
Description: Surgical implantation of aorto-bifemoral bypass or aorta stentgraft under general and/or regional anaesthesia.
Study: NCT03365102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS over the lOFC,
Description: tDCS at a constant current of 1.5 mA will be applied for one 20-minute session over the left orbitofrontal cortex . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS stimulation condition
Description: In the sham condition, the current will be ramped up to 1.5 mA for 30 seconds and then ramped back down to 0. As this commonly used sham procedure produces a brief tingling sensation, participants are kept unaware of their experimental condition. Resting-state EEG for 10 minutes will be recorded immediately prior to and after the sham tDCS. After post-sham stimulation resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
Study: NCT00954486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: Epoetin alfa will be administered at 10,000 units/week
Study: NCT02163564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: A non-pharmacological therapy for insomnia based on behavior and cognitive therapy approaches
Study: NCT02177695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, 1000 mg/m2, IV (in the vein) on Days 1 and 8 of each 21 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 70 mg/m2, IV (in the vein) on Day 1 of each 21 day cycle (or Day 1 or 2 of each 14 day cycle).~Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 70 mg/m2, IV (in the vein) on Day 1 of each 21 day cycle (or Day 1 or 2 of each 14 day cycle).~Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
Study: NCT00468104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: 25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days
Study: NCT02177695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine, 3 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim, 5 mcg/kg, SubQ/IV (in the vein) on Days 3-7 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
Study: NCT02859220

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of PTH following
Description: Determination of PTH following:~in group 1: intact PTH Elecsys Roche

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of PTH following:
Description: PTH 1-84 complete (PAC) report and CAP / CIP, the package Duo PTH IRMA Scantibodies. The CIP is obtained by calculating the difference between total intact PTH and PTH 1-84 in the kit used.
Study: NCT02786849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation of high frequency and intensity
Description: Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: frequency of 50 Hz, pulse width 400ms, rise time and 2s descent, stimulus mode on-off starting with a ratio of 1: 2 in the first week (stimulus time of 10 seconds and rest time of 20s, aiming at adaptation and mitigation of the effects of muscle fatigue), evolving from the second week to a ratio of 1:1 (stimulation time of 10 seconds and rest time of 10s).~The current intensity is adjusted individually for the first application and gradually increased as the tolerance of patients.~In each session there will be a warm-up period, training and slowdown. The intensity will be the maximum tolerated by the patient in order increments every session, this being monitored for further evolutionary calculating.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation of low frequency and intensity
Description: Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: 5 Hz frequency, time on: off 1: 3 with a pulse duration of 100ms.~The current intensity is adjusted individually for the first application and it was the least noticeable by the patient.~In each session there will be a warm-up period, training and slowdown.
Study: NCT04236817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-packed blisters for distribution of medications

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine distribution of medications
Study: NCT05313295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy
Description: Manual Therapy, passive and active mobilizations, stretching, respiratory techniques

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physiotherapy
Description: Usual care provided for the management of neurological disorders in children
Study: NCT02698696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECo program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRT program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive psychotherapy
Study: NCT01190397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warming goggles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: warm and moist compresses
Study: NCT01852877

Intervention type: BEHAVIORAL
Intervention: Corrections case management
Description: Corrections case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.

Intervention type: BEHAVIORAL
Intervention: Corrections case management
Description: Corrections case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.
Study: NCT03446794

Intervention type: OTHER
Intervention: Non Intervention
Description: To assess the procedural safety and efficacy on stroke and bleeding prevention of LAAC in patients with NVAF and ESCKD on HD
Study: NCT03085095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection
Study: NCT04154072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NLY01
Description: exenatide and polyethylene glycol (PEG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NLY01
Description: exenatide and polyethylene glycol (PEG)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Saline (Sodium Chloride)
Study: NCT00468104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: 25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
Study: NCT01782027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3H-cholesterol bound to albumin
Description: up to 100 uCi of \[3H\]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection